作者: Nathan A Pennell , Lecia V Sequist
关键词: Gefitinib 、 Oncology 、 Non small cell 、 Copy-number variation 、 Medicine 、 Bioinformatics 、 Lung cancer 、 Protein expression 、 EGFR inhibitors 、 Internal medicine 、 Epidermal growth factor receptor 、 Mutation
摘要: Evaluation of: Hirsch FR, Varella-Garcia M, Bunn PA Jr et al.: Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5034–5042 (2006) [1]. In this article, we critically evaluate recent publication that assessed molecular clinical benefit from treatment gefitinib, small-molecule inhibitor the epidermal growth factor receptor (EGFR), patients EGFR inhibitors, such as have previously been shown to preferentially distinct subgroups cancer patients, and strategies prospectively identify these are under active investigation. study, authors analyzed tissue randomized trial examine association after protein expression, gene copy number, mutations other potential predictive markers. The ...